LTBP2: A Potential Drug Target and Biomarker (G4053)

Target Name: LTBP2

NCBI ID: G4053

LTBP2

LTBP2: A Potential Drug Target and Biomarker

Latent Transforming Growth Factor Beta (LTBP2) is a protein that is expressed in various tissues, including the brain, heart, and kidneys, and plays a crucial role in cell growth and development. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, LTBP2 has become an attractive target for drug development, with researchers studying its potential as a potential therapeutic intervention.

The LTBP2 protein is a member of the transforming growth factor family, which is a group of proteins that play a critical role in cell growth and development. This family of proteins includes several different isoforms, including LTBP1, LTBP2, and GTF2, which are involved in a variety of cellular processes, including cell proliferation, differentiation, and survival.

LTBP2 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, and kidneys. It is highly conserved, with a calculated pI of 5.9, and is able to interact with several different proteins, including the transcription factor, p53, and the protein kinase, p300.

One of the key functions of LTBP2 is its role in cell proliferation. It is a negative regulator of the cell cycle, which means that it promotes the growth of cells in the S phase and inhibits the G1 phase. This regulation is critical for the growth and development of tissues, and is implicated in the development of cancer.

In addition to its role in cell proliferation, LTBP2 is also involved in several other cellular processes that are important for normal development and function. For example, it is a critical regulator of neurogenesis, the process by which new neurons are generated in the brain, and is involved in the formation of neural stem cells. It is also involved in the regulation of inflammation, and has been shown to play a role in the development of autoimmune diseases.

Despite its involvement in several important cellular processes, the role of LTBP2 in disease pathology is not yet fully understood. Several studies have suggested that LTBP2 may be involved in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the most promising areas of research surrounding LTBP2 is its potential as a drug target. Several studies have shown that LTBP2 is a good candidate for small molecule inhibitors, which could be used to treat a variety of diseases. For example, studies have shown that inhibiting the activity of LTBP2 has the potential to inhibit the growth and survival of cancer cells, and may be an effective treatment for cancer.

Another promising area of research surrounding LTBP2 is its potential as a biomarker. Several studies have shown that LTBP2 is expressed in a variety of tissues and is involved in several important cellular processes, making it an attractive candidate for use as a biomarker. This could be useful for the diagnosis and monitoring of diseases, as well as for the development of new therapies.

In conclusion, LTBP2 is a protein that is involved in several important cellular processes and has been implicated in a number of diseases. As a result, it is an attractive target for drug development and research into its potential as a biomarker. Further studies are needed to fully understand the role of LTBP2 in disease pathology and its potential as a therapeutic intervention.

Protein Name: Latent Transforming Growth Factor Beta Binding Protein 2

Functions: May play an integral structural role in elastic-fiber architectural organization and/or assembly

The "LTBP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LTBP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets